Form 10-Q Hims & Hers Health, Inc. For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
BTIG Reiterates Buy Rating on Hims and Hers (HIMS), PT $85
August 5, 2025 9:32 AM EDTBTIG analyst David Larsen reiterated a Buy rating and $85.00 price target on Hims and Hers (NYSE: HIMS).
The analyst comments " On Monday, AMC, HIMS reported 2Q:25 results. Revenue of $544.8M +73% y/y was behind BTIG / consensus of $560.9M / $552M though adjusted EBITDA of $82.2M was well ahead of BTIG / consensus of $80.4M / $73M. Excluding several increases in costs related to hiring new talent, EBITDA would have been closer to ~$90M. Relative to our model, the... More
Hims and Hers (HIMS) PT Raised to $43 at Leerink Partners
August 5, 2025 6:36 AM EDTLeerink Partners analyst Michael Cherny raised the price target on Hims and Hers (NYSE: HIMS) to $43.00 (from $42.00) while maintaining a Market Perform rating.
The analyst comments "Bottom Line: HIMS appears to be in somewhat of a transitory stage, with the companys first revenue miss driven by both the sequential (expected) decline in GLP-1 revenue and the sequential (unexpected) decline in core revenue outside of GLP-1s. We... More
